The intricate mechanism through which UMODL1 accelerating tumor proliferation of Her-2 positive breast cancer as well as trastuzumab resistance

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Abstr act: Human epidermal growth factor receptor 2 positive breast cancer is characterized by the overexpression of the Her-2 receptor, rapid tumor growth, strong invasion ability, and high resistance to chemotherapy. Targeted drug therapies for this subtype include trastuzumab and pertuzumab; however, some patients still show resistance to these treatments. The Uromodulin-1-like (UMODL1) gene, also known as Olfactorin, has been identified as a prognostic indicator for survival in patients with esophageal squamous cell carcinoma, lung adenocarcinoma, and colorectal cancer. UMODL1 expression is increased in both Her-2 positive breast cancer cell lines and trastuzumab-resistant cell lines. Elevated UMODL1 promotes the proliferation and migration of breast cancer cells while reducing apoptosis; on the contrary, suppressed UMODL1 has opposite effects. UMODL1 upregulates the expression of Her-2 and binds with Her-2 heterodimers to activate downstream signaling pathways associated with Her-2 activation. This mechanism contributes to the development and progression of Her-2-positive breast cancer while also affecting trastuzumab resistance. In summary, these findings indicate that UMODL1 can serve as a prognostic indicator of survival in patients with Her-2 positive breast cancer while providing guidance on the use of trastuzumab.

Article activity feed